 | Curis (NASDAQ:CRIS) Stock Price Down 6%
americanbankingnews.com - March 4 at 7:38 PM |
 | Curis to Present at HC Wainwright & Co. Global Life Sciences Conference - PRNewswire
prnewswire.com - March 2 at 12:00 PM |
| Curis (NASDAQ:CRIS) Shares Up 6%
americanbankingnews.com - March 1 at 9:00 PM |
 | Curis: Differentiated IRAK4 Inhibitor To Drive Value Creation In The Near Term - Seeking Alpha
seekingalpha.com - March 1 at 3:54 PM |
| Head-To-Head Comparison: Curis (NASDAQ:CRIS) & Replimune Group (NASDAQ:REPL)
americanbankingnews.com - February 27 at 2:08 AM |
| Reviewing Curis (NASDAQ:CRIS) and VIA Pharmaceuticals (OTCMKTS:VIAP)
americanbankingnews.com - February 21 at 12:12 AM |
| Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference - PRNewswire
prnewswire.com - February 19 at 12:15 PM |
 | Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference
finance.yahoo.com - February 19 at 12:15 PM |
| Curis (NASDAQ:CRIS) Shares Down 5.1%
americanbankingnews.com - February 18 at 7:26 PM |
| How Many Curis, Inc. (NASDAQ:CRIS) Shares Do Institutions Own? - Yahoo Finance
finance.yahoo.com - February 18 at 7:49 AM |
|
| How Many Curis, Inc. (NASDAQ:CRIS) Shares Do Institutions Own?
finance.yahoo.com - February 17 at 11:41 AM |
| Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies - Yahoo Finance
finance.yahoo.com - February 11 at 2:33 PM |
| Curis (NASDAQ:CRIS) Shares Gap Up to $9.76
americanbankingnews.com - February 11 at 1:45 PM |
 | Curis Doses First Patient In Phase 1 Study Of CA-4948 - Nasdaq
nasdaq.com - February 9 at 5:45 PM |
| Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies - PRNewswire
prnewswire.com - February 9 at 12:45 PM |
 | Indapta Therapeutics Announces Key Management Team Appointments to Advance into Clinical Trials in 2021 - StreetInsider.com
streetinsider.com - February 3 at 1:49 PM |
| Curis Initiates Phase 2 LUCAS Study Of CA-4948 For Treatment Of Anemia - Nasdaq
nasdaq.com - February 2 at 7:09 PM |
| Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes - PRNewswire
prnewswire.com - February 2 at 9:07 AM |
| Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes
finance.yahoo.com - February 2 at 9:07 AM |
| Taseko Announces Upsizing and Pricing of Senior Secured Notes Offering - Yahoo Finance
finance.yahoo.com - January 27 at 10:27 PM |
 | RUBY Stock Price, Rubius Therapeutics Stock Quotes and News - Benzinga
benzinga.com - January 27 at 5:26 PM |
| Taseko Announces Upsizing and Pricing of Senior Secured Notes Offering - PRNewswire
prnewswire.com - January 27 at 5:26 PM |
| Curis Inc.: Understanding CI-8993 And VISTA - Seeking Alpha
seekingalpha.com - January 27 at 12:26 PM |
| Curis to Present at B. Riley Securities Virtual Oncology Investor Conference - Yahoo Finance
finance.yahoo.com - January 14 at 3:42 PM |
| Curis to Present at B. Riley Securities Virtual Oncology Investor Conference
finance.yahoo.com - January 14 at 3:42 PM |
| Curis to Present at H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference - Yahoo Finance
finance.yahoo.com - January 5 at 12:26 PM |
| Curis to Present at H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference
finance.yahoo.com - January 5 at 12:26 PM |
| Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition - Seeking Alpha
seekingalpha.com - December 23 at 8:03 PM |
|
| Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition
seekingalpha.com - December 23 at 4:53 PM |
| CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors
finance.yahoo.com - December 22 at 5:06 PM |
| Curis Announces Closing of Public Offering of Common Stock with $169.6 Million in Gross Proceeds, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Yahoo Finance
finance.yahoo.com - December 14 at 8:52 PM |
| Curis Announces Closing of Public Offering of Common Stock with $169.6 Million in Gross Proceeds, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PRNewswire
prnewswire.com - December 14 at 10:50 AM |
| Curis Announces Closing of Public Offering of Common Stock with $169.6 Million in Gross Proceeds, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - December 14 at 10:50 AM |
| Curis (CRIS) Surges: Stock Moves 5% Higher - Nasdaq
nasdaq.com - December 11 at 12:00 PM |
| Curis (CRIS) Surges: Stock Moves 5% Higher
finance.yahoo.com - December 11 at 12:00 PM |
| Is CRIS A Good Stock To Buy Now?
finance.yahoo.com - December 11 at 1:59 AM |
| Stock Alert: Curis Shares Gain After Pricing Of Public Offering - Nasdaq
nasdaq.com - December 10 at 3:55 PM |
| Curis Announces Pricing of Public Offering of Common Stock - PRNewswire
prnewswire.com - December 10 at 3:55 PM |
| Curis prices equity offering at $5.75/share - Seeking Alpha
seekingalpha.com - December 10 at 5:51 AM |
| Curis (CRIS) Stock Is up 420% in Two Days. How Much Higher Can It Go? - Yahoo Finance
finance.yahoo.com - December 9 at 7:51 PM |
| Curis (CRIS) Skyrockets on Promising Phase I Pipeline Updates - Yahoo Finance
finance.yahoo.com - December 9 at 7:51 PM |
| Curis (CRIS) Stock Is up 420% in Two Days. How Much Higher Can It Go?
finance.yahoo.com - December 9 at 7:51 PM |
| Curis Announces Pricing of Public Offering of Common Stock - Yahoo Finance
finance.yahoo.com - December 9 at 2:50 PM |
| Curis (CRIS) Skyrockets on Promising Phase I Pipeline Updates
finance.yahoo.com - December 9 at 2:50 PM |
| Curis Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - December 9 at 2:50 PM |
| Curis readies equity raise - Seeking Alpha
seekingalpha.com - December 8 at 9:16 PM |
 | Curis skyrockets 448% after encouraging phase 1 data for leukemia treatment - Business Insider
businessinsider.com - December 8 at 9:16 PM |
| Curis, Lexicon Pharmaceuticals leads healthcare gainers; Obalon Therapeutics, Arcturus Therapeutics among major losers - Seeking Alpha
seekingalpha.com - December 8 at 4:16 PM |
| Return On Capital Employed Overview: Curis - Benzinga
benzinga.com - December 8 at 4:16 PM |
| Why Is It Moving? Looking Into Why Curis's Stock is Trading Higher Today - Benzinga
benzinga.com - December 8 at 4:16 PM |
